+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver transplant recipients

Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver transplant recipients

Transplant International 7(Suppl. 1): S235

Epstein-Barr virus (EBV) infection is recognized as the principal aetiological factor in the pathogenesis of post-transplant lymphoproliferative disease (PTLD), particularly when primary EBV infection occurs after transplantation. We analysed, using a time-dependent proportional hazards model, the factors associated with development of PTLD in 40 adult liver transplant recipients who were seronegative for EBV prior to transplantation. Of 40 patients, 13 (33%) had a tissue diagnosis of PTLD at a median time of 126 days after transplantation. The multivariate analysis showed that prior CMV disease, the number of steroid boluses given and the number of units of RBC and FFP transfused were significant risk factors for development of PTLD.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 046067922

Download citation: RISBibTeXText

PMID: 11271213

Related references

Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV) - seronegative adult liver transplant recipients. Transplant International 7(Suppl. S1): 235-237, 1994

Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases. Transplant Infectious Disease 7(3-4): 133-136, 2005

Expression of epstein barr virus encoded small rnas ebers in liver biopsies precedes development of post transplant lymphoproliferative disease ptld. Laboratory Investigation 66(1): 99A, 1992

Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. American Journal of Transplantation 5(3): 566-572, 2005

Epstein-Barr virus-related post transplant lymphoproliferative disease of donor origin in two orthotopic liver transplant recipients. Hepatology 22(4 Part 2): 210A, 1995

The use of objective case ascertainment to identify risk factors for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder in pediatric liver transplant recipients. Hepatology 36(4 Part 2): 662A, 2002

Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clinical Transplantation 20(3): 389-393, 2006

Pre-transplant seronegative Epstein-Barr virus status is the primary risk factor for post-transplant lymphoproliferative disorder in adult heart and lung and other solid organ transplantations. Journal of Heart and Lung Transplantation 13(1 Part 2): S54, 1994

Hepatitis C virus infection can affect lymphoproliferative disorders only as a cofactor for Epstein-Barr virus in liver transplant recipients: PTLD.Int survey. Experimental and Clinical Transplantation 10(2): 141-147, 2012

EBNA 1 and BZLF1 plus IgG serum levels individuate early stages of Epstein Barr virus -related post transplant lymphoproliferative disease and helps modulation of immune suppression in liver transplant recipients. Hepatology 28(4 Part 2): 268A, 1998

Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation. European Journal of Haematology 101(3): 283-290, 2018

Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease. Journal of Medical Virology 69(2): 258-266, 2003

The role of real-time PCR assay for prevention of Epstein-Barr virus-associated post-transplant lymphoproliferative disease in renal transplant recipients. Journal of Urology 165(5 Suppl.): 385, 2001

Severe cold agglutinin disease caused by recurrent monomorphic Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD), clonally related to an EBV-negative plasmacytic hyperplasia in a pediatric multivisceral organ transplant recipient. Pediatric Transplantation 11(5): 547-551, 2007

Elevated levels of Epstein Barr virus DNA determined by semi-quantitative PCR and the presence of post-transplant lymphoproliferative disease in organ transplant recipients. Blood 90(10 Suppl. 1 Part 1): 77A, 1997